Key result
Intravenous digoxin offered no significant advantage over placebo for conversion of recent onset atrial fibrillation to sinus rhythm (47.4% vs 40.0%; ns).
Why the study?
Does intravenous digoxin improve conversion to sinus rhythm or rate control in patients with recent onset atrial fibrillation?
Population
40 patients with recent onset (< 1 week) atrial fibrillation (not due to haemodynamic alternations)
Comparison
Digoxin 1.25 mg administered intravenously vs Intravenous saline (placebo)
Design
RCT, randomized, double-blind
Follow-up
12 to 24 hours
Authors
Loading...
IV digoxin should not be used for conversion in recent-onset AF; confirms lack of benefit and supports alternative strategies.
RCT (n=40)
Double-blind
Does intravenous digoxin improve conversion to sinus rhythm or rate control in patients with recent onset atrial fibrillation?
Absolute Event Rate: 47.4% vs 40%
p-value: p=ns
Intravenous digoxin offers no substantial advantages over placebo for conversion of recent onset atrial fibrillation and provides only weak rate control.
Jordaens et al. (1997) conducted an RCT in Recent onset atrial fibrillation (n=40). Digoxin vs. Placebo (saline intravenously) was evaluated on Conversion to sinus rhythm within 12 h (p=ns). Intravenous digoxin offered no significant advantage over placebo for conversion of recent onset atrial fibrillation to sinus rhythm (47.4% vs 40.0%; ns).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: